Literature DB >> 25643820

Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone.

J Smith1, M Kiupel2, J Farrelly3, R Cohen4, G Olmsted3, J Kirpensteijn5, B Brocks5, G Post3.   

Abstract

Grade II mast cell tumours (MCT) are tumours with variable biologic behaviour. Multiple factors have been associated with outcome, including proliferation markers. The purpose of this study was to determine if extent of surgical excision affects recurrence rate in dogs with grade II MCT with low proliferation activity, determined by Ki67 and argyrophilic nucleolar organising regions (AgNOR). Eighty-six dogs with cutaneous MCT were evaluated. All dogs had surgical excision of their MCT with a low Ki67 index and combined AgNORxKi67 (Ag67) values. Twenty-three (27%) dogs developed local or distant recurrence during the median follow-up time. Of these dogs, six (7%) had local recurrence, one had complete and five had incomplete histologic margins. This difference in recurrence rates between dogs with complete and incomplete histologic margins was not significant. On the basis of this study, ancillary therapy may not be necessary for patients with incompletely excised grade II MCT with low proliferation activity.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  Ag67; AgNOR; Ki67; mast cell tumours

Mesh:

Substances:

Year:  2015        PMID: 25643820     DOI: 10.1111/vco.12140

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  8 in total

1.  The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.

Authors:  Fabio Gentilini; Maria Elena Turba; Claire Dally; Masamine Takanosu; Sena Kurita; Makoto Bonkobara
Journal:  BMC Vet Res       Date:  2020-02-19       Impact factor: 2.741

2.  Long-term postsurgical outcomes of mast cell tumors resected with a margin proportional to the tumor diameter in 23 dogs.

Authors:  Teruo Itoh; Atsuko Kojimoto; Kazuyuki Uchida; James Chambers; Hiroki Shii
Journal:  J Vet Med Sci       Date:  2020-12-21       Impact factor: 1.267

Review 3.  Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.

Authors:  Andrigo Barboza de Nardi; Rodrigo Dos Santos Horta; Carlos Eduardo Fonseca-Alves; Felipe Noleto de Paiva; Laís Calazans Menescal Linhares; Bruna Fernanda Firmo; Felipe Augusto Ruiz Sueiro; Krishna Duro de Oliveira; Silvia Vanessa Lourenço; Ricardo De Francisco Strefezzi; Carlos Henrique Maciel Brunner; Marcelo Monte Mor Rangel; Paulo Cesar Jark; Jorge Luiz Costa Castro; Rodrigo Ubukata; Karen Batschinski; Renata Afonso Sobral; Natália Oyafuso da Cruz; Adriana Tomoko Nishiya; Simone Crestoni Fernandes; Simone Carvalho Dos Santos Cunha; Daniel Guimarães Gerardi; Guilherme Sellera Godoy Challoub; Luiz Roberto Biondi; Renee Laufer-Amorim; Paulo Ricardo de Oliveira Paes; Gleidice Eunice Lavalle; Rafael Ricardo Huppes; Fabrizio Grandi; Carmen Helena de Carvalho Vasconcellos; Denner Santos Dos Anjos; Ângela Cristina Malheiros Luzo; Julia Maria Matera; Miluse Vozdova; Maria Lucia Zaidan Dagli
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

4.  Outcomes of adjunctive radiation therapy for the treatment of mast cell tumors in dogs and assessment of toxicity: A multicenter observational study of 300 dogs.

Authors:  Sarah L Mason; Charles Pittaway; Begona Pons Gil; Onne-Marju Russak; Katie Westlake; Davide Berlato; Jérôme Benoit; Joanna Morris; Jane Margaret Dobson
Journal:  J Vet Intern Med       Date:  2021-10-21       Impact factor: 3.333

5.  Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study.

Authors:  Shawna Klahn; Nikolaos Dervisis; Kevin Lahmers; Marian Benitez
Journal:  Vet Sci       Date:  2022-06-07

6.  Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.

Authors:  Pamela D Jones; Justine E Campbell; Graham Brown; Chad M Johannes; Paul Reddell
Journal:  J Vet Intern Med       Date:  2020-12-22       Impact factor: 3.175

Review 7.  Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal.

Authors:  Michael Willmann; Vilma Yuzbasiyan-Gurkan; Laura Marconato; Mauro Dacasto; Emir Hadzijusufovic; Olivier Hermine; Irina Sadovnik; Susanne Gamperl; Mathias Schneeweiss-Gleixner; Karoline V Gleixner; Thomas Böhm; Barbara Peter; Gregor Eisenwort; Richard Moriggl; Zhixiong Li; Mohamad Jawhar; Karl Sotlar; Erika Jensen-Jarolim; Veronika Sexl; Hans-Peter Horny; Stephen J Galli; Michel Arock; David M Vail; Matti Kiupel; Peter Valent
Journal:  Front Vet Sci       Date:  2021-12-10

8.  Beclin-1 is a novel predictive biomarker for canine cutaneous and subcutaneous mast cell tumors.

Authors:  Britta J Knight; Geoffrey A Wood; Robert A Foster; Brenda L Coomber
Journal:  Vet Pathol       Date:  2021-09-14       Impact factor: 2.221

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.